Wells Fargo & Company Apellis Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$507 Billion
Q3 2025

A detailed history of Wells Fargo & Company transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 2,463 shares of APLS stock, worth $50,072. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,463

Previous 1,043,655 99.76%

Holding current value

$50,072

Previous $18.1 Million 99.7%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$17.42 - $28.65 $18.1 Million - $29.8 Million	-1,041,192 Reduced 99.76%	2,463 $55,000
Q2 2025 Aug 14, 2025	BUY	$16.36 - $23.0 $17 Million - $23.9 Million	1,039,031 Added 22470.39%	1,043,655 $18.1 Million
Q1 2025 May 13, 2025	SELL	$21.87 - $34.63 $21,695 - $34,352	-992 Reduced 17.66%	4,624 $101,000
Q4 2024 Feb 12, 2025	SELL	$26.18 - $35.42 $3.5 Million - $4.74 Million	-133,752 Reduced 95.97%	5,616 $179,000
Q3 2024 Nov 13, 2024	SELL	$28.84 - $41.15 $601,602 - $858,389	-20,860 Reduced 13.02%	139,368 $4.02 Million

Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $578,397 - $907,174	15,193 Added 10.48%	160,228 $6.15 Million
Q1 2024 May 10, 2024	BUY	$55.39 - $72.47 $690,602 - $903,555	12,468 Added 9.41%	145,035 $8.53 Million
Q4 2023 Feb 09, 2024	SELL	$37.14 - $64.82 $859,419 - $1.5 Million	-23,140 Reduced 14.86%	132,567 $7.94 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $1.5 Million - $5.67 Million	63,512 Added 68.89%	155,707 $5.92 Million
Q2 2023 Aug 15, 2023	SELL	$76.68 - $93.31 $1.03 Million - $1.25 Million	-13,423 Reduced 12.71%	92,195 $8.4 Million
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $4.13 Million - $5.94 Million	88,673 Added 523.3%	105,618 $6.97 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $114,715 - $161,939	-2,653 Reduced 13.54%	16,945 $876,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $169,908 - $264,429	3,796 Added 24.02%	19,598 $1.34 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $898,388 - $1.52 Million	-25,617 Reduced 61.85%	15,802 $714,000
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $798,062 - $1.22 Million	-22,506 Reduced 35.21%	41,419 $2.11 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $409,948 - $655,597	13,336 Added 26.36%	63,925 $3.02 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $451,846 - $1 Million	14,390 Added 39.75%	50,589 $1.67 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $1.07 Million - $1.7 Million	26,162 Added 260.66%	36,199 $2.29 Million
Q1 2021 May 13, 2021	SELL	$40.8 - $57.39 $1.57 Million - $2.2 Million	-38,386 Reduced 79.27%	10,037 $430,000
Q4 2020 Feb 09, 2021	BUY	$30.79 - $57.2 $676,117 - $1.26 Million	21,959 Added 82.98%	48,423 $2.77 Million
Q3 2020 Nov 05, 2020	SELL	$25.89 - $33.65 $365,981 - $475,676	-14,136 Reduced 34.82%	26,464 $799,000
Q2 2020 Aug 13, 2020	BUY	$24.8 - $38.49 $243,734 - $378,279	9,828 Added 31.94%	40,600 $1.33 Million
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $551,126 - $1.36 Million	30,772 New	30,772 $825,000

Others Institutions Holding APLS

# of Institutions

329

Shares Held

124M

Call Options Held

4.12M

Put Options Held

756K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Apellis Pharmaceuticals, Inc. Transaction History